FDA Approves Acalabrutinib to Treat CLL/SLL
As part of Project Orbis, The FDA has approved acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - November 21, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Supplemental New Drug Application -- submitted through FDA Real-Time Oncology Review program -- is based on positive Phase 3 data in patients aged 70 or younger
RARITAN, N.J., Nov. 8, 2019 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharma... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, Johnson & Johnson, IMBRUVICA, ibrutinib (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 8, 2019 Category: Pharmaceuticals Source Type: news
UCLA Health partners with Kareem Abdul-Jabbar on health and wellness
UCLA legend and NBA Hall of Famer Kareem Abdul-Jabbar is teaming up with UCLA Health for a wide variety of new health and wellness initiatives designed to improve health and prevent disease.The partnership will be announced at the 2019 Leukemia and Lymphoma Society ’s Los Angeles Light the Night Walk, an event for which UCLA Health is the presenting sponsor. The Los Angeles Laker superstar and UCLA Bruin basketball player is a survivor of chronic myeloid leukemia, or CML, which is a form of blood cancer. To honor his survivorship, Abdul-Jabbar has served as an ambassador and UCLA Health fundraising team captain at the...
Source: UCLA Newsroom: Health Sciences - November 7, 2019 Category: Universities & Medical Training Source Type: news
Risk for Second Primary Malignancy Up in CLL Survivors
FRIDAY, Nov. 1, 2019 -- Survivors of chronic lymphocytic leukemia (CLL) have an increased risk for second primary malignancy (SPM), according to a study published online Sept. 30 in Blood Cancer Journal.
Vivek Kumar, M.D., from Harvard Medical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 1, 2019 Category: Pharmaceuticals Source Type: news
PHARMAC funding venetoclax for chronic lymphocytic leukaemia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 31, 2019 Category: Drugs & Pharmacology Source Type: news
Antibody eradicates leukemia stem cells
The introduction of the drug imatinib in 2001 revolutionized the treatment of a type of cancer called chronic myelogenous leukemia. In more than 80% of people with CML who received the drug, the disease went into complete remission.However, in most people with chronic myelogenous leukemia, cancerous stem cells remain in the body for years after their cancer has gone into remission. If treatment with imatinib or another similar medication is stopped — and in some cases, even while treatment continues — the leukemia stem cells can cause cancer to recur.Now, in experiments in mice as well as isolated human cancer cells, U...
Source: UCLA Newsroom: Health Sciences - October 15, 2019 Category: Universities & Medical Training Source Type: news
Risk of Infectious Complications in Patients with Chronic Lymphocytic Leukemia in the Era of BCR Inhibitors: A Retrospective Single Institution Experience
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 8, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Hypertension & CV Adverse Events With Ibrutinib in'Real World'Hypertension & CV Adverse Events With Ibrutinib in'Real World '
Ibrutinib has changed the treatment landscape of chronic lymphocytic leukemia, but emerging real-world data suggest caution, owing to hypertension and other CV adverse events.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 8, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Invasive Aspergillosis in Chronic Lymphocytic Leukemia: Therapy and Outcomes
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 6, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Blast Count Prognostic for CML Presenting in Advanced Phase
THURSDAY, Sept. 26, 2019 -- Blast count seems to be the main prognostic count for patients with chronic myeloid leukemia (CML) presenting in an advanced phase, according to a study published online Aug. 27 in the American Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 26, 2019 Category: Pharmaceuticals Source Type: news
Chronic Lymphocytic Leukemia: 5 Things to Know Chronic Lymphocytic Leukemia: 5 Things to Know
The most common adult leukemia has seen a rush of new evidence in recent years. Here are some of the highlights.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 24, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news
Leukemia drug shows promise for treating a childhood brain cancer
A drug used to treat chronic myeloid leukemia appears to be more effective at stopping a type of medulloblastoma in mouse models than existing treatments for the deadly pediatric brain tumor, reports a multi-institutional team led by researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego. (Source: World Pharma News)
Source: World Pharma News - September 23, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Epidemiology and Risk Factors of Invasive Fungal Infections Among 795 Patients with Chronic Lymphocytic Leukemia from the Padua University
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 22, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Practical Dosing Considerations for Venetoclax
With FDA-approved indications for both chronic lymphocytic leukemia and acute myeloid leukemia, and continued investigation within multiple disease states, venetoclax has become an exciting oral targeted therapy among oncologists. (Source: CancerNetwork)
Source: CancerNetwork - September 20, 2019 Category: Cancer & Oncology Authors: Kelly Valla, PharmD, BCOP Source Type: news
Chronic Myeloid Leukemia: 5 Things to Know Chronic Myeloid Leukemia: 5 Things to Know
In the wake of the tyrosine kinase inhibitor revolution, where is the treatment of CML headed?Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 17, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news
